U.S. Companion Animal Health Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

U.S. Companion Animal Health Market Trends and Insights

Premiumization and Humanization of Pet Healthcare

The United States companion animal health market is experiencing a shift as households increasingly prioritize pets and invest in their care. By 2025, the pet industry spending reached USD 158 billion, with veterinary care contributing USD 41.4 billion, making it a key category.^{[1]American Pet Products Association, “U.S. Pet Industry Reaches USD 158 Billion in 2025, Poised for Continued Growth in 2026,” APPA News, americanpetproducts.org} This trend drives demand for advanced diagnostics, chronic disease treatments, and specialty services, moving beyond routine wellness. Clinics are adopting comprehensive treatment plans, while manufacturers and service providers expand premium offerings in oncology, pain management, dermatology, and long-term monitoring.

Pet Insurance Expansion and Financing-Led Care Acceptance

Pet insurance is becoming a critical driver of treatment acceptance in the United States companion animal health market. In 2025, direct premiums written reached USD 5.47 billion, reflecting double-digit growth. Expanding coverage enables pet owners to access advanced imaging, specialist referrals, and multi-drug protocols, particularly in high-cost treatments.^{[2]Insurance Information Institute, “Triple-I Highlights Growing Insurance Needs for Pet Owners and Pet Care Businesses,” Morningstar, morningstar.com} Financing tools at clinics further support this trend by making expensive care more accessible at the decision point.

AI-Enabled Diagnostics and Workflow Integration

The integration of AI into diagnostics and workflows is advancing the United States companion animal health market. In 2026, IDEXX expanded its oncology testing portfolio with mast cell tumor testing for dogs, complementing its Cancer Dx Panel. Faster interpretations and seamless workflow integration encourage in-clinic testing over outsourcing. However, limited transparency in veterinary AI products highlights the need for stronger standards, which could benefit established suppliers. AI adoption in imaging, pathology, and clinical management is expected to enhance productivity and revenue consistency.

Vector-Borne Disease Preparedness and Screwworm Resilience

Vector-borne diseases are driving demand for parasiticides, vaccines, and screenings in the United States companion animal health market. In 2026, Zoetis emphasized screwworm preparedness, while Merck Animal Health received FDA approval for BRAVECTO QUANTUM, offering expanded tick protection. Disease mapping is becoming critical for product strategies, especially in high-risk regions like Southern states and border areas. Longer-duration preventive products are gaining traction, ensuring better compliance and reducing missed treatments.

High Out-of-Pocket Treatment Costs

Affordability remains a key challenge in the United States companion animal health market. High treatment costs delay wellness visits, reduce diagnostic follow-through, and limit specialist procedure adoption despite clinical demand. Missed routine visits impact service revenue and related product sales. Specialty care faces the greatest pressure as costs outpace household budgets, restricting access to premium offerings. Without broader insurance and financing options, out-of-pocket expenses will continue to constrain growth outside higher-income households.

Consolidator Formulary Discipline and Online Pharmacy Competition

The United States companion animal health market is experiencing a channel shift that affects branded product sales. Large veterinary groups are tightening procurement processes, while online pharmacies capture refill demand previously retained by clinics. This reduces in-clinic sales of oral therapies and maintenance products, especially with easy price comparisons. However, clinic-administered injectables and biologics remain less exposed to retail competition, driving manufacturers to focus on categories where clinics retain control over prescribing and administration.

Segment Analysis

By Animal Type: Feline Spending Accelerates as Canine Base Matures

In 2025, dogs held 59.35% of the United States companion animal health market share, driven by higher treatment frequency in areas like orthopedics, dental care, and cardiology. The adoption of biologic therapies further boosted revenue, with over 1 million dogs treated with Librela by early 2025, showcasing the rapid scaling of high-value pain management products. Dogs remain the primary revenue anchor, even as growth stabilizes.

Cats are projected to grow at an 11.15% CAGR from 2026 to 2031, making them the fastest-growing segment in the United States companion animal health market. This growth is supported by species-specific innovations, such as a feline liquid biopsy prototype with 97% specificity for lymphoma detection and the launch of RapidRead Dental for Feline. Equine and other companion animals maintain stable demand through preventive care and specialized treatments.

By Product Type: Diagnostics Redefines the Revenue Architecture of the Clinic

Therapeutics accounted for 43.25% of the United States companion animal health market revenue in 2025, benefiting from new approvals and label expansions for chronic and specialty conditions. Key developments include VETMEDIN's clearance for preclinical myxomatous mitral valve disease and NUMELVI's approval for managing pruritus in dogs. The focus is shifting toward pain management, monoclonal antibodies, and chronic disease treatments.

Diagnostics is forecast to grow at a 12.75% CAGR from 2026 to 2031, becoming the fastest-growing product category. Clinics are adopting tools that streamline workflows, such as SDMA kidney biomarker testing integrated into Catalyst chemistry profiles. While digital health platforms are emerging, diagnostics stands out as a key driver of revenue growth through workflow integration.

By Indication: Oncology Pipeline Converts Unmet Need into Market Value

Infectious diseases led the United States companion animal health market in 2025, accounting for 35.78% of revenue, driven by vaccine compliance, parasite prevention, and tick-borne disease management. Expanded tick coverage in products like BRAVECTO QUANTUM highlights the industry's response to evolving risks. Pain and inflammation treatments are also growing due to longer treatment pathways for aging animals.

Oncology is projected to grow at an 11.63% CAGR from 2026 to 2031, driven by earlier detection and expanded diagnostic and treatment windows. IDEXX's Cancer Dx Panel for canine lymphoma has reached nearly 6,000 veterinary practices, establishing a strong diagnostic base. Endocrine and metabolic disorders and cardiology are also advancing with new approvals and label expansions.

By Distribution Channel: Clinic-Led Dispensing Faces Structural Pressure

Veterinary hospital and clinic pharmacies held 65.89% of the United States companion animal health market revenue in 2025, supported by integrated diagnosis, prescription, and administration processes. High-value products like monoclonal antibodies and in-clinic diagnostics reinforce the clinic's role, while retail pharmacies cater to routine OTC items and supplements.

E-commerce and online pharmacies are forecast to grow at a 10.95% CAGR from 2026 to 2031, driven by refill convenience, auto-ship programs, and price transparency. Chewy's acquisition of Modern Animal reflects the shift toward a comprehensive care model combining clinics, pharmacies, and virtual support. Smaller channels like compounding pharmacies and mobile veterinary services address niche needs effectively.

Geography Analysis

High veterinary spending, a strong network of clinics, and a favorable product approval environment drive consistent launches in diagnostics, biologics, and therapeutics. The broader United States pet industry is expected to grow from USD 158 billion in 2025 to USD 165 billion in 2026, supporting continued healthcare investments. Premium demand is strongest in metropolitan areas like California, New York, Texas, and Florida, where higher pet density, household income, and access to specialty care enable greater adoption of advanced treatments.

Regional disparities in access limit market growth, particularly in rural areas of the South, Appalachia, and the Great Plains, where routine-care access gaps, longer travel times, and fewer specialty providers persist. These challenges delay diagnoses, hinder follow-up care, and restrict treatment adoption outside urban centers. Virtual support and care navigation tools are expanding to address these gaps. For instance, whiskerDocs announced in May 2026 its focus on chronic and preventive care as pets live longer.

Regional disease exposure also shapes market demand. Southern border states, the Gulf Coast, and the Southwest face higher risks of vector-borne diseases, driving demand for parasiticides, vaccines, and screening. In 2026, Zoetis emphasized screwworm preparedness, while Merck's BRAVECTO QUANTUM approval reflected the industry's response to evolving tick exposure patterns. Insurance adoption and digital service availability remain stronger in urban markets, with slower growth in rural areas.